ANGO
AngioDynamics, Inc. NASDAQ Listed Jun 1, 2004$11.27
Mkt Cap $465.7M
52w Low $8.36
51.7% of range
52w High $13.99
50d MA $10.81
200d MA $11.04
P/E (TTM)
-13.4x
EV/EBITDA
208.4x
P/B
2.5x
Debt/Equity
0.0x
ROE
-21.7%
P/FCF
-28.6x
RSI (14)
—
ATR (14)
—
Beta
0.43
50d MA
$10.81
200d MA
$11.04
Avg Volume
429.3K
AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. The company provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation systems; and radiofrequency ablation products for ablating solid cancerous or benign tumors. It also offers BioSentry tract sealant systems, IsoLoc Endorectal Balloon's, alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. In addition, the company provides endovascular therapies products in the areas of thrombus management, atherectomy, peripheral products (Core), and venous insufficiency. Additionally, the company offers peripherally inserted central catheters, midline catheters, implantable ports, dialysis catheters, and related accessories and supplies that are used primarily to deliver short-term drug therapies, such as chemotherapeutic agents and antibiotics, into the central venous system under the BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax names. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York.
14 Plaza Drive · Latham, NY 12110 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 2, 2026 | AMC | -0.11 | -0.07 | +36.4% | 10.31 | +0.1% | -4.6% | -5.9% | -1.4% | -2.1% | -4.9% | — |
| Jan 6, 2026 | AMC | -0.10 | -0.15 | -50.0% | 11.44 | -1.2% | -4.5% | -12.2% | -13.8% | -11.0% | -12.0% | — |
| Oct 2, 2025 | AMC | -0.14 | -0.10 | +28.6% | 11.74 | +0.3% | -0.9% | -4.1% | -5.9% | -5.3% | -5.1% | — |
| Jul 15, 2025 | AMC | -0.13 | -0.03 | +76.9% | 8.65 | +4.2% | -0.6% | +1.0% | +0.5% | +3.9% | +5.5% | — |
| Apr 2, 2025 | AMC | -0.13 | 0.03 | +123.1% | 10.86 | -6.4% | -9.6% | -16.1% | -14.3% | -17.1% | -12.1% | — |
| Jan 8, 2025 | AMC | -0.11 | -0.04 | +63.6% | 12.94 | -0.9% | -4.9% | -3.7% | -8.8% | -6.0% | -1.3% | — |
| Oct 3, 2024 | AMC | -0.15 | -0.11 | +26.7% | 6.37 | +0.8% | -4.2% | -4.2% | -7.7% | -4.6% | -3.6% | — |
| Jul 16, 2024 | AMC | -0.20 | -0.06 | +70.0% | 7.51 | +1.1% | -1.5% | -7.5% | -4.4% | -5.1% | -0.4% | — |
| Apr 4, 2024 | AMC | -0.14 | -0.16 | -14.3% | 6.40 | +9.1% | +9.8% | +3.3% | +8.9% | +7.0% | +6.2% | — |
| Jan 5, 2024 | AMC | -0.09 | -0.05 | +44.4% | 6.21 | -1.3% | +2.7% | +0.8% | -0.3% | -2.4% | -3.4% | — |
| Oct 4, 2023 | AMC | -0.14 | -0.12 | +14.3% | 7.40 | +3.2% | -3.4% | -4.5% | -4.7% | -0.2% | -5.5% | — |
| Jul 12, 2023 | AMC | 0.02 | 0.02 | -11.1% | 9.77 | +2.9% | -0.8% | -1.4% | -2.1% | -0.3% | -8.7% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 6 | Canaccord Genuity | Maintains | Buy → Buy | — | $10.31 | $10.32 | +0.1% | -4.6% | -5.9% | -1.4% | -2.1% | -4.9% |
| Oct 3 | Canaccord Genuity | Maintains | Buy → Buy | — | $11.74 | $11.77 | +0.3% | -0.9% | -4.1% | -5.9% | -5.3% | -5.1% |
| Jul 16 | Canaccord Genuity | Maintains | Buy → Buy | — | $8.65 | $9.01 | +4.2% | -0.6% | +1.0% | +0.5% | +3.9% | +5.5% |
| Jul 16 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.65 | $9.01 | +4.2% | -0.6% | +1.0% | +0.5% | +3.9% | +5.5% |
| Apr 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.11 | $9.01 | -1.1% | +2.2% | -1.2% | +4.8% | +1.4% | +2.0% |
| Jan 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.94 | $12.82 | -0.9% | -4.9% | -3.7% | -8.8% | -6.0% | -1.3% |
| Jan 9 | Canaccord Genuity | Maintains | Buy → Buy | — | — | — | — | — | — | — | — | — |
| Dec 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.63 | $8.69 | +0.7% | +3.0% | +5.6% | +6.4% | +4.3% | +8.1% |
| Oct 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.37 | $6.42 | +0.8% | -4.2% | -4.2% | -7.7% | -4.6% | -3.6% |
| Oct 4 | Canaccord Genuity | Maintains | Buy → Buy | — | $6.37 | $6.42 | +0.8% | -4.2% | -4.2% | -7.7% | -4.6% | -3.6% |
| Sep 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.70 | $7.65 | -0.6% | -2.1% | -2.6% | -1.6% | -3.9% | -2.5% |
| Jul 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.51 | $7.59 | +1.1% | -1.5% | -7.5% | -4.4% | -5.1% | -0.4% |
| Jul 17 | Canaccord Genuity | Maintains | Buy → Buy | — | $7.51 | $7.59 | +1.1% | -1.5% | -7.5% | -4.4% | -5.1% | -0.4% |
| May 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.86 | $5.89 | +0.5% | +7.8% | +4.4% | +5.3% | +6.5% | +4.6% |
| Apr 5 | Oppenheimer | Upgrade | Perform → Outperform | — | $6.40 | $6.98 | +9.1% | +9.8% | +3.3% | +8.9% | +7.0% | +6.2% |
| Jan 9 | Raymond James | Maintains | Outperform → Outperform | — | $6.38 | $6.27 | -1.7% | -1.9% | -3.0% | -5.0% | -6.0% | -6.9% |
| Jan 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.21 | $6.13 | -1.3% | +2.7% | +0.8% | -0.3% | -2.4% | -3.4% |
| Oct 6 | Raymond James | Maintains | Outperform → Outperform | — | $7.15 | $7.11 | -0.6% | -1.1% | -1.4% | +3.3% | -2.2% | -10.3% |
| Oct 5 | Canaccord Genuity | Maintains | Buy → Buy | — | $7.40 | $7.64 | +3.2% | -3.4% | -4.5% | -4.7% | -0.2% | -5.5% |
| Oct 5 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.40 | $7.64 | +3.2% | -3.4% | -4.5% | -4.7% | -0.2% | -5.5% |
| Jul 13 | Canaccord Genuity | Maintains | Buy → Buy | — | $9.77 | $10.05 | +2.9% | -0.8% | -1.4% | -2.1% | -0.3% | -8.7% |
| Apr 17 | Raymond James | Downgrade | Strong Buy → Outperform | — | $9.09 | $8.90 | -2.1% | -0.1% | -3.4% | -1.7% | -2.6% | -2.1% |
| Apr 3 | Raymond James | Maintains | Strong Buy → Strong Buy | — | $10.34 | $10.41 | +0.7% | -4.4% | -7.5% | -7.8% | -7.9% | -9.4% |
| Jan 6 | Raymond James | Maintains | Strong Buy → Strong Buy | — | $15.48 | $15.49 | +0.1% | -2.0% | -5.9% | -13.0% | -13.9% | -11.2% |
| Oct 7 | Raymond James | Maintains | Strong Buy → Strong Buy | — | $17.34 | $17.16 | -1.0% | -8.3% | -17.1% | -22.9% | -19.0% | -14.7% |
| Jul 13 | Raymond James | Maintains | Strong Buy → Strong Buy | — | $20.02 | $19.73 | -1.4% | +4.5% | +3.5% | +6.5% | +3.8% | +5.5% |
| Oct 15 | Canaccord Genuity | Upgrade | Hold → Buy | — | $25.76 | $27.19 | +5.6% | +6.2% | +5.7% | +7.9% | +10.1% | +11.6% |
| Aug 20 | Oppenheimer | Maintains | Perform → Perform | — | $27.36 | $27.25 | -0.4% | +2.2% | +1.7% | +2.0% | +1.1% | +0.8% |
| Jul 14 | Canaccord Genuity | Maintains | Hold → Hold | — | $27.44 | $27.41 | -0.1% | -3.7% | -5.0% | -5.3% | -9.8% | -5.9% |
| Jul 9 | Raymond James | Maintains | Strong Buy → Strong Buy | — | $27.32 | $27.90 | +2.1% | +2.9% | +4.0% | +0.4% | -3.3% | -4.6% |
| Mar 31 | Canaccord Genuity | Maintains | Hold → Hold | — | $22.47 | $22.79 | +1.4% | +4.1% | +3.0% | +4.9% | +7.1% | +5.0% |
| Jan 8 | Raymond James | Maintains | Strong Buy → Strong Buy | — | $18.57 | $19.00 | +2.3% | -0.0% | +2.9% | -0.4% | +0.1% | +0.2% |
| Nov 25 | Raymond James | Upgrade | Market Perform → Strong Buy | — | $13.03 | $15.06 | +15.6% | +10.4% | +10.2% | +9.1% | +6.3% | +6.5% |
| Apr 8 | Canaccord Genuity | Maintains | Hold → Hold | — | $10.44 | $10.06 | -3.6% | -4.7% | +0.3% | -8.2% | -8.2% | -13.3% |
| Apr 8 | KeyBanc | Downgrade | Overweight → Sector Weight | — | $10.44 | $10.06 | -3.6% | -4.7% | +0.3% | -8.2% | -8.2% | -13.3% |
| Apr 8 | KeyBanc Capital Markets | Downgrade | Overweight → Sector Weight | — | $10.44 | $10.06 | -3.6% | -4.7% | +0.3% | -8.2% | -8.2% | -13.3% |
| Oct 4 | KeyBanc | Maintains | Overweight → Overweight | — | $15.16 | $14.52 | -4.2% | -3.7% | -3.4% | -3.7% | -3.9% | -4.8% |
| Oct 4 | KeyBanc Capital Markets | Maintains | Overweight → Overweight | — | $15.16 | $14.52 | -4.2% | -3.7% | -3.4% | -3.7% | -3.9% | -4.8% |
| Jan 7 | Canaccord Genuity | Maintains | Hold → Hold | — | $21.52 | $21.65 | +0.6% | -3.6% | -2.3% | -3.7% | -3.3% | -3.6% |
| Apr 3 | Raymond James | Upgrade | Market Perform → Outperform | — | $17.42 | $18.12 | +4.0% | +5.6% | +8.8% | +9.3% | +8.4% | +8.9% |
| Apr 2 | Canaccord Genuity | Maintains | Hold → Hold | — | $17.25 | $17.29 | +0.2% | +1.0% | +6.6% | +9.9% | +10.4% | +9.4% |
| Jul 19 | Barclays | Maintains | Equal Weight → Equal Weight | — | $15.12 | $15.03 | -0.6% | +0.9% | +4.2% | +3.5% | +11.1% | +13.2% |
| Feb 8 | Barclays | Maintains | Equal Weight → Equal Weight | — | $16.22 | $16.23 | +0.1% | -0.6% | -0.7% | +2.6% | +3.1% | +2.3% |
| Nov 4 | Cantor Fitzgerald | Maintains | Buy → Buy | — | $15.52 | $15.92 | +2.6% | +2.1% | +3.9% | +4.3% | +3.1% | +6.4% |
| Apr 5 | Canaccord Genuity | Downgrade | Buy → Hold | — | $12.14 | $11.50 | -5.3% | -8.8% | -7.4% | -4.3% | -9.4% | -11.2% |
| Nov 10 | Raymond James | Downgrade | Outperform → Market Perform | — | $12.95 | $12.60 | -2.7% | -7.4% | -8.4% | -9.2% | -9.4% | -8.5% |
| Sep 23 | Sidoti & Co. | Maintains | Neutral → Neutral | — | $14.59 | $14.54 | -0.3% | -1.1% | -1.4% | -3.1% | -8.1% | -9.4% |
| Jul 24 | KeyBanc | Maintains | Outperform → Outperform | — | $15.60 | $15.78 | +1.2% | +0.1% | +0.2% | -1.3% | -1.5% | -2.5% |
| Jul 24 | Raymond James | Maintains | Outperform → Outperform | — | $15.28 | $15.89 | +4.0% | -7.4% | -7.9% | -6.3% | -4.8% | -3.9% |
| Jun 19 | Canaccord Genuity | Upgrade | Hold → Buy | — | $15.31 | $16.00 | +4.5% | +4.5% | +5.6% | +5.1% | +3.9% | +5.2% |
No insider trades available.
8-K · 8.01
!! High
AngioDynamics, Inc. -- 8-K 8.01: Material Event / Announcement
AngioDynamics initiated a patent infringement lawsuit against Endovascular Engineering over its H-lo Thrombectomy System, alleging unauthorized use of AngioDynamics' self-expanding funnel technology for thrombus removal.
Apr 23
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
ANGO disclosed material information via Regulation FD, signaling the company proactively communicates with investors, but forward-looking statement disclaimers suggest upcoming guidance carries execution risk investors should evaluate carefully.
Apr 2
8-K · 5.02
!!! Very High
AngioDynamics, Inc. -- 8-K 5.02: Executive Change
AngioDynamics appointed James C. Clemmer as a director, expanding its board with new governance oversight for the medical device company's strategic initiatives.
Feb 3
Data updated apr 24, 2026 6:09pm
· Source: massive.com